Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 26,414,170	$ 33,794,672
Receivable due from collaboration agreement	1,776,583	1,628,703
Research and development tax incentive receivable	1,168,830	966,646
Prepaid assets and other current assets	2,164,451	2,447,930
Total current assets	31,524,034	38,837,951
Property and equipment, net	2,258,738	1,859,860
Total assets	33,782,772	40,697,811
Current liabilities:
Accounts payable	2,028,779	1,493,842
Accrued compensation		416,910
Deferred research grant revenue	168,000	50,000
Total liabilities	2,196,779	1,960,752
Commitments and contingencies (see Note 4)
Stockholders’ equity:
Common stock; $0.001 par value, 45,000,000 shares authorized; 25,371,781 shares issued and outstanding	25,372	25,372
Additional paid-in capital	105,256,670	104,078,968
Accumulated other comprehensive loss	(1,687)	(48,921)
Accumulated deficit	(73,694,362)	(65,318,360)
Total stockholders’ equity	31,585,993	38,737,059
Total liabilities and stockholders’ equity	$ 33,782,772	$ 40,697,811